Cancer News
Cancer Education and Research Institute® (CERI)'s Cancer Education Programs
Our Team of cancer experts at Cancer Education and Research Institute® (CERI)'s, formerly Cancer Research Simplified, provides you with the most reliable, most up-to-date, and simplified cancer information available. Our educational programs quickly became trusted and highly sought after worldwide.
CERI strongly stands behind the importance of cancer patient empowerment and is a worldwide leading source for simplified, multi-language cancer education. Knowledge is power and empowerment is the key for greater treatment success, early diagnosis, as well as cancer prevention.
For any questions or requests, please submit your inquiry at our CERI Personalized Patient Program™ page.
CERI strongly stands behind the importance of cancer patient empowerment and is a worldwide leading source for simplified, multi-language cancer education. Knowledge is power and empowerment is the key for greater treatment success, early diagnosis, as well as cancer prevention.
For any questions or requests, please submit your inquiry at our CERI Personalized Patient Program™ page.
New Research - Glioblastoma Treatment
Researchers have discovered a novel approach to successfully treat the fatal brain cancer - Glioblastoma
Aygün Sahin, MSc, PhD | CEO, President, and Cancer Lead, Cancer Education and Research Institute (CERI)
What is Gliobastoma multiforme (Glioblastoma)?
Glioblastoma is the most invasive, aggressive, and deadly form of adult brain cancer. Current treatment involves surgery, chemotherapy, and radiotherapy. Despite these therapies, not only that it often comes back, the lifespan of a treated patient is less than 12 months.
New research: Combo therapy with Viruses and Immunotherapy
A two-phase clinical trial was conducted by an international team of researchers, which included Drs. Farshad Nassiri and Gelareh Zadeh from the University Health Network (UHN) in Toronto, resulted in the discovery of a novel approach for the successful treatment of fatal brain cancer.
The treatment follows a two-step process and has displayed positive outcomes in a two-phase clinical trial.
STEP 1: The initial step involves the doctors administering an "oncolytic" virus straight into the tumor, which has a specific task- targeting and eliminating cancer cells.
STEP 2: The second step involved intravenous immunotherapy, with patients receiving an anti-PD-1 antibody designed to prevent cancer from evading the immune system. The outcomes have been promising, offering hope for those affected by this devastating disease.
Glioblastoma is the most invasive, aggressive, and deadly form of adult brain cancer. Current treatment involves surgery, chemotherapy, and radiotherapy. Despite these therapies, not only that it often comes back, the lifespan of a treated patient is less than 12 months.
New research: Combo therapy with Viruses and Immunotherapy
A two-phase clinical trial was conducted by an international team of researchers, which included Drs. Farshad Nassiri and Gelareh Zadeh from the University Health Network (UHN) in Toronto, resulted in the discovery of a novel approach for the successful treatment of fatal brain cancer.
The treatment follows a two-step process and has displayed positive outcomes in a two-phase clinical trial.
STEP 1: The initial step involves the doctors administering an "oncolytic" virus straight into the tumor, which has a specific task- targeting and eliminating cancer cells.
STEP 2: The second step involved intravenous immunotherapy, with patients receiving an anti-PD-1 antibody designed to prevent cancer from evading the immune system. The outcomes have been promising, offering hope for those affected by this devastating disease.
|
|
The results of this breakthrough approach have shown prolonged survival rates and complete eradication of tumors.
By combining oncolytic virus and immunotherapy, researchers found that the treatment was safe and well-tolerated, and not only led to improved patient survival rates for 12.5 months but also resulted in some tumors shrinking or disappearing completely. This was particularly remarkable as the patients in the trial did not undergo tumor resection, receiving only the virus injection. This marks a new treatment approach for glioblastoma.
By combining oncolytic virus and immunotherapy, researchers found that the treatment was safe and well-tolerated, and not only led to improved patient survival rates for 12.5 months but also resulted in some tumors shrinking or disappearing completely. This was particularly remarkable as the patients in the trial did not undergo tumor resection, receiving only the virus injection. This marks a new treatment approach for glioblastoma.
An additional Genetic Discovery
In addition to these promising results, the researchers also discovered a new genetic signature within tumor samples. They believe that this new genetic signature could help predict which patients are most likely to respond to the treatment.
In addition to these promising results, the researchers also discovered a new genetic signature within tumor samples. They believe that this new genetic signature could help predict which patients are most likely to respond to the treatment.
The next steps
The researchers aim to conduct a randomized clinical trial to compare the effectiveness of the combination therapy with other treatments, taking their findings to the next level.
The researchers aim to conduct a randomized clinical trial to compare the effectiveness of the combination therapy with other treatments, taking their findings to the next level.
Summary
The promising results of the study provide a significant advancement in the treatment of glioblastoma, a highly aggressive and deadly form of adult brain cancer.
The innovative method and identification of a new genetic marker have the potential to lead to more individualized therapies in the future, bringing optimism to those affected by the disease and their loved ones.
Moving forward, the researchers plan to conduct a randomized clinical trial to compare the effectiveness of this combination therapy with other available treatments. There is still much work to be done, but this study marks a significant step forward.
The promising results of the study provide a significant advancement in the treatment of glioblastoma, a highly aggressive and deadly form of adult brain cancer.
The innovative method and identification of a new genetic marker have the potential to lead to more individualized therapies in the future, bringing optimism to those affected by the disease and their loved ones.
Moving forward, the researchers plan to conduct a randomized clinical trial to compare the effectiveness of this combination therapy with other available treatments. There is still much work to be done, but this study marks a significant step forward.
Watch the video in which we share some more details about glioblastoma:
Please donate to support our program - help us save MORE lives!
If you would like to read the research article:
References:
- Nassiri, F., Patil, V., Yefet, L.S. et al. Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial. Nat Med (2023). https://www.nature.com/articles/s41591-023-02347-y (accessed May 16, 2023)
- Scientists find new way to treat deadly brain cancer effectively. Knowrigde. https://knowridge.com/2023/05/scientists-find-new-way-to-treat-deadly-brain-cancer-effectively (accessed May 16, 2023)
You might also like to watch these videos:
|
|
|
Do you need help with cancer diagnosis?
Please fill the application form on our CERI Personalized Patient Program page - we CAN help you!
#Empowermentagainstcancer™ #CERICancerEducation #CERICares
#cancer #glioblastoma #gbm #clinicaltrial #immunotherapy #chemotherapy #cancerfree #eradicatingcancer #metastaticcancer #cancereducation #cancerresearch #cancertreatment #canceredinstitute
GET YOUR FREE ARTICLE: Make sure to get your free article as our gift to you! Go to: canceredinstitute.org/ceri-simplified-cancer-research-articles
CORONAVIRUS PAGE: For our educational and up-to-date informational page on Coronavirus, go to: canceredinstitute.org/coronavirus
FOLLOW US for DAILY information and updates:
CORONAVIRUS PAGE: For our educational and up-to-date informational page on Coronavirus, go to: canceredinstitute.org/coronavirus
FOLLOW US for DAILY information and updates:
- INSTAGRAM: instagram.com/canceredinstitute
- FACEBOOK: facebook.com/canceredinstitute
- Twitter: twitter.com/canceredinst
- LinkedIn: linkedin.com/company/canceredinstitute
You might also like:
|
|
|
Disclaimer: We can not assume responsibility of misinterpretation of content.
